Reconsolidation using Rewind

The RETURN Study: REconsolidaTion Using RewiNd

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91345822

Enrollment

Registered

2020-01-23

Start date

2020-10-01

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Traumatic Stress Disorder (PTSD) Mental and Behavioural Disorders Post Traumatic Stress Disorder (PTSD)

Interventions

This is a cross-over waitlist controlled RCT. The total duration of treatment will be three 60 minute sessions. One arm of the study will start Rewind post-randomisation, with the second group remaini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 years or over who are fluent in English 2. Able to provide informed consent 3. Meet DSM-5 criteria for PTSD

Exclusion criteria

Exclusion criteria: 1. Current psychotic or bipolar disorder 2. Traumatic brain injury 3. Substance dependence 4. Acute suicidal ideation 5. Personality disorder 6. Learning disability 7. Previous receipt of an adequate trial of trauma-focused psychological treatment for PTSD 8. Change to the type or dosage of psychotropic medication within one month of baseline assessment

Design outcomes

Primary

Measure	Time frame
PTSD symptom severity measured using the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at 8 and 16 weeks post-randomisation	—

Secondary

Measure	Time frame
Measured at 8 and 16 weeks post-randomisation (unless otherwise noted): 1. PTSD symptoms (DSM-5) measured using the PTSD Checklist (PCL-5) at the start of each treatment session 2. ICD-11 PTSD and complex PTSD symptoms measured using the International Trauma Questionnaire 3. DSM-5 depressive symptoms measured using the PHQ-9 at the start of each treatment session 4. Symptoms of generalised anxiety disorder measured using the GAD-7 at the start of each treatment session 5. Symptoms of insomnia measured using the Insomnia Severity Index 6. Health-related quality of life measured using the EQ5D-5L 7. An intervention acceptability questionnaire will be administered by the Rewind therapist at the end of the final session to gauge acceptability and feasibility of the intervention, as perceived by the participant	—

Measure

Time frame

Measured at 8 and 16 weeks post-randomisation (unless otherwise noted): 1. PTSD symptoms (DSM-5) measured using the PTSD Checklist (PCL-5) at the start of each treatment session 2. ICD-11 PTSD and complex PTSD symptoms measured using the International Trauma Questionnaire 3. DSM-5 depressive symptoms measured using the PHQ-9 at the start of each treatment session 4. Symptoms of generalised anxiety disorder measured using the GAD-7 at the start of each treatment session 5. Symptoms of insomnia measured using the Insomnia Severity Index 6. Health-related quality of life measured using the EQ5D-5L 7. An intervention acceptability questionnaire will be administered by the Rewind therapist at the end of the final session to gauge acceptability and feasibility of the intervention, as perceived by the participant

—

Countries

United Kingdom, Wales

Contacts

Public ContactLaurence Astill Wright

laurencewright@doctors.org.uk+44 (0)29 2068 8113

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 16, 2026